NON-HODGKIN LYMPHOMA,B CELL

This early-stage study tests a new treatment called SynKIR-310 for adults with B-cell non-Hodgkin lymphoma that has come back or not responded to at least two prior therapies. The treatment uses a patient's own immune cells, modified to better recognize and attack cancer cells. T…

This study looks at whether CAR T cell therapy can be safely given to people with blood cancers who also have moderate to severe kidney problems. Researchers will adjust the standard chemotherapy given before the CAR T cells to protect the kidneys. The goal is to see how often si…

This early study tests a new type of cell therapy called universal CAR-T cells in people with relapsed or treatment-resistant B-cell non-Hodgkin lymphoma. The therapy targets a protein called CD19 on cancer cells. Up to 6 adults will receive the treatment to check safety and how …

This early-phase study tests a new type of CAR-T cell therapy (BRL-201) for adults with B-cell non-Hodgkin lymphoma that has come back or not responded to other treatments. The therapy uses a patient's own immune cells, modified to target cancer cells and designed to be safer by …

This study tests a new drug, MEN1703, alone or with another drug (glofitamab) in adults with aggressive B-cell lymphoma that has come back or not responded to at least two prior treatments. The goal is to see if the treatment is safe and shrinks tumors. About 178 participants wil…

This study follows 1,500 people with B-cell non-Hodgkin lymphoma in Italy who are receiving new monoclonal antibody treatments. Researchers will track how well the tumors shrink, how long patients live without the cancer getting worse, and any side effects. The goal is to see how…

This study is observing 130 adults with B-cell non-Hodgkin lymphoma who are scheduled to receive CAR-T cell therapy. Researchers want to see if having low muscle mass (sarcopenia) affects how well the treatment works and what side effects occur. The goal is to learn whether a sim…